Potential detectability of blood flow in hepatocellular carcinoma using contrast-enhanced ultrasonography with Sonazoid (Comparison with transvenous contrast-enhanced computed tomography or computed tomography with angiography)

Potential detectability of blood flow in hepatocellular carcinoma using contrast-enhanced ultrasonography with Sonazoid (Comparison with transvenous contrast-enhanced computed tomography or computed tomography with angiography) - Potential detectability of tumor blood flow using contrast-enhanced ultrasonography

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015389

Enrollment

100

Registered

2014-10-10

Start date

2008-07-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Microbubble contrast agents

Sonazoid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1. Egg allergy 2. Severe lung disease 3. Severe heart disease 4. Hepatocellular carcinomas are not supplied by hepatic artery. 5. Tumors are diagnosed not to be hepatocellular carcinomas. 6. Determined to be ineligible by the physician in charge for any other reason.

Design outcomes

Primary

Measure	Time frame
Potential detectability of tumor blood flow using contrast-enhanced ultrasonography, intravenous contrast-enhaced computed tomography, and computed tomography with angiography	—

Countries

Japan

Contacts

Public ContactHitoshi Maruyama

Chiba University Graduate School of Medicine Department of Gastroenterology and Nephrology

maru-cib@umin.ac.jp043-226-2083

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026